Multidisciplinary approach to patient with malignant melanoma

Giuseppina Della Vittoria Scarpati, Celeste Fusciello, Francesco Sabbatino, Soldano Ferrone, Francesco Caponigro, Francesco Perri, Chiara Carlomagno, Stefano Pepe

Research output: Contribution to journalArticlepeer-review


The incidence of melanoma is rapidly increasing worldwide and the prognosis of patients with metastatic disease is still poor, with a median survival of 8-9 months and a 3-year overall survival (OS) rate less than 15% [1,2]. A complete surgical excision is the main treatment for primary cutaneous melanoma [3], but controversies about the extension of excision margins still remain [4]. Sentinel lymph node biopsy (SLNB) provides important prognostic and staging data by the identification of regional node-negative patients who would not benefit from a complete nodal dissection. However, there is no consensus in the definition of melanoma thickness to enforce the execution of the SLNB [5]. To date, Interferon-α (IFN-α)is the only approved adjuvant treatment after surgical excision of high-risk melanoma, but its indication remains still controversial [2,6].

Original languageEnglish
Pages (from-to)887-900
Number of pages14
JournalAnti-Cancer Agents in Medicinal Chemistry
Issue number6
Publication statusPublished - 2013


  • B-RAF inibithors
  • Chemotherapy
  • Immunotherapy
  • Melanoma

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Pharmacology


Dive into the research topics of 'Multidisciplinary approach to patient with malignant melanoma'. Together they form a unique fingerprint.

Cite this